China Inc. Eyes Gene Therapy In Post-Coronavirus Growth Trajectory
Large Patient Pool An Advantage?
Eyeing a largely untapped treatment area and huge patient pool, biotechs in China are leaping into the gene therapy foray despite the lack of a distinct regulatory pathway or reimbursement of the highly costly treatments.
You may also be interested in...
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
China releases technical requirements for foreign drug makers to register their chemical drugs in the country, and issues patent linkage details, which a legal expert says needs to be closely examined.